Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

Clinical Pharmacokinetics

Volumn 41, Issue 5, 2002, Pages 343-370

  Williams, David ^a   Feely, John ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMIODARONE; ANTACID AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; CHOLESTEROL; CIMETIDINE; CISAPRIDE; CREATINE KINASE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LANOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; SQUALENE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FOOD DRUG INTERACTION; HUMAN; HYPERLIPIDEMIA; MUSCLE NECROSIS; MYALGIA; MYOPATHY; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR;

EID: 0036291921     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241050-00003     Document Type: Review

References (256)

1. Drug-related morbidity and mortality: A cost of illness model
2. Increase in US medication-error deaths between 1983 and 1993
3. Reducing errors in medicine
4. Adverse drug events in hospitalised patients. Excess length of stay, extra costs, and attributable mortality
5. The costs of adverse drug events in hospitalised patients
6. Adverse drug interactions
7. Principles of therapeutics
8. Drug interactions and the statins
9. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
10. Extending therapy options in treating lipid disorders: A clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival study (4S)
12. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
13. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
14. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
15. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
16. Prevention of coronary heart disease with pravastatin in men with hpercholesterolaemia
17. Cholesterol lowering in the elderly population
18. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholestoral concentrations: The LIPID trial follow-up
19. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials
20. Statins are the new aspirin, Oxford Researchers say
21. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention
22. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S)
23. Coronary and cardiovascular risk estimation for primary prevention: Validation of a new Sheffield table in the 1995 Scottish health survey population
24. Updated New Zealand cardiovascular disease risk-benefit prediction guide
25. Growth in use of statins after trials is not targeted to most appropriate patients
26. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)
27. Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events
28. US spending on prescription drugs rose by 19% in 2000
29. Cholesterol lowering and the use of healthcare resources
30. Simvastatin: A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease
31. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population
32. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase
33. Efficacy and long term adverse effect pattern of lovastatin
34. Choosing the right lipid-regulating agent
35. Expanded clinical evaluation of lovastatin (EXCEL) study results. IV. Additional perspectives on the tolerability of lovastatin
36. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias
37. Current perspectives on statins
38. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil
39. Bayer decides to withdraw cholesterol lowering drug
40. HMG-CoA reductase inhibitors for the treatment of hypercholesterolaemia
41. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
42. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporin
43. Biochemical and clinical consequences of inhibiting coenzyme Q10 biosynthesis by lipid lowering HMG-CoA reductase inhibitors (statins): A critical overview
44. HMG-CoA reductase inhibitors and myotoxicity
45. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
46. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
47. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors - Similarities and differences
48. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy
49. Polypharmacy: The cure becomes the disease
50. A review of medication errors and compliance in ambulant patients
51. Drug-related problems causing admission to a medical clinic
52. 'Fire and forget' - Pharmacological considerations in coronary care
53. Drug interactions of lipid-altering drugs
54. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin
55. Physiological disposition of HMG-CoA-reductase inhibitors
56. The physiological disposition of lovastatin
57. Clinical pharmacokinetics of pravastatin
58. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters
59. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects
60. Single-dose pharmacokinetics of pravastatin and metabotites in patients with renal impairment
61. Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease
62. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue-selective inhibition of sterol synthesis and hypolipidaemic effects on various animal species
63. Effects of pravastatin on cholesterol metabolism in Watanabe heritable hyperlipidaemic rabbits
64. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
65. Differentiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors by their relative lipophilicity
66. Simvastatin: A review of its pharmacological properties and potential in hypercholesterolaemia
67. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug
68. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin
69. Ascending multiple dose safety, tolerability and pharmacokinetics of rivastatin in humans
70. Influence of erythromycin pre- and co-treatment on the single-dose pharmacokinetics of cerivastatin
71. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
72. Preclinical and clinical pharmacotogy of cerivastatin
73. Atorvastatin calcium: An addition to HMG-CoA reductase inhibitors
74. Fluvastatin: A review of its use in lipid disorders
75. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers
76. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions
77. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
78. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glyco-protein: Implications for drug delivery and activity in cancer chemotherapy
79. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
80. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
81. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers
82. Inhibition of P-glycoprotein-mediated drag transport: A unifying mechanism to explain the interaction between digoxin and quinidine
83. HMG-CoA reductase inhibitors and P-glycoprotein modulation
84. Interaction between fibre and lovastatin
85. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolaemia
86. Drug interaction between simvastatin and cholestyramine in vitro and in vivo
87. Pharmacokinetics of fluvastatin and specific drug interactions
88. Influence of cholestyramine on the pharmacokinetics of cerivastatin
89. Effect of food on pravastatin pharmacokinetics and pharmacodynamics
90. Clinical implications of the biopharmaceutical properties of fluvastatin
91. Pharmacokinetics of cerivastatin administration with and without food in the morning and evening
92. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor
93. Fluvastatin. A review of its pharmacology and use in the management of hypercholesterolaemia
94. Grapefruit-felodipine interaction: Mechanism, predictability, and effect of naringin
95. Trough concentrations of cyclosporin in blood following administration with grapefruit juice
96. Interaction between grapefruit juice and midazolam in humans
97. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarisation on the electrocardiogram
98. Drug interactions with grapefruit juice
99. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
100. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
101. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid
102. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
103. Effect of itraconazole on the pharmacokinetics of atorvastatin
104. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
105. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
106. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole
107. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin
108. Effects of HMG CoA reductase inhibitors on warfarin binding
109. Effect of simvastatin on cyclosporin unbound fraction and apparent blood clearance in heart transplant recipients
110. The interaction of diltiazem with lovastatin and pravastatin
111. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
112. Differential metabolism of statins: Importance of drug-drug interactions
113. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors - The role of metabolism: Monograph for physicians
114. Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine
115. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
116. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isoenzymes (CYP2C9, CYP2D6 and CYP 3A4) by HMG-CoA reductase inhibitors
117. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
118. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver
119. Biotransformation of lovastatin. III. Effect of cimetidine and famotidine on in-vitro metabolism of lovastatin by rat and human liver microsomes
120. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes
121. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
122. Interaction between lovastatin and cyclosporin A after heart and kidney transplantation
123. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
124. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporin-treated kidney graft patients after multiple doses
125. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation
126. Low-dose lovastatin in hyperlipidemic kidney graft recipients with cyclosporine A
127. Lovastatin treatment of hyperlipidemia in kidney transplant recipients on cyclosporine immunosuppression
128. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin
129. Lovastatin and rhabdomyolysis
130. Coadministration of itraconazole with hypolipidaemic agents may induce rhabdomyolysis in healthy individuals
131. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations
132. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs
133. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients
134. The effects of pravastatin on hyperlipidaemia in renal transplant recipients
135. Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics
136. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin
137. Effect of orlistat, a novel anti-obesity agent, on the pharmacokinetics and pharmacodynamics of pravastatin in patients with mild hypercholesterolaemia
138. Possible interaction between nefazodone and pravastatin
139. Comment: Possible interaction between nefazodone and pravastatin
140. Plasma concentration profiles of simvastatin 3-hydroxy-3 methylglutaryl-co-enzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin
141. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient
142. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
143. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients
144. The interaction of diltiazem with simvastatin
145. Calcium channel blocker-simvastatin interaction
146. Rhabdomyolysis due to interaction of simvastatin with mibefradil
147. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone
148. Rhabdomyolysis induced by simvastatin and ketoconazole treatment
149. Drug-interaction-induced rhabdomyolysis
150. Rhabdomyolysis attributed to HMG-CoA-reductase inhibitor-warfarin interaction
151. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin
152. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
153. Efficacy of statin therapy: Possible effect of phenytoin
154. Macrolide antibacterials -drug interactions of clinical significance
155. Minor alterations in cerivastatin pharmacokinetics by erythromycin and itraconazole
156. Effect of itraconazole on cerivastatin pharmacokinetics
157. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients
158. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile
159. Inhibition of rhodamine 123 secretion by cyclosporin A as a model of P-glycoprotein mediated transport in liver
160. Bayer faces potential fine over cholesterol lowering drug
161. Erythromycin coadministration increases plasma atorvastatin concentrations
162. Acute rhabdomyolysis after atorvastatin and fusidic acid therapy
163. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin
164. Cytochrome P450: New nomenclature and clinical implications
165. Pharmacokinetic and pharmacodynamic interactions of fluvastatin and their therapeutic implications
166. Updated clinical safety experience with fluvastatin
167. ZD4522 - A new HMG-CoA reductase inhibitor - Causes rapid and profound reductions in plasma LDL-C levels in patients with primary hypercholesterolaemia
168. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus nonhepatic cells
169. ZD4522-An HMGCo-A reductuse inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems
170. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects
171. Lovastatin-warfarin interaction
172. Pravastatin: Possible interaction with oral anticoagulant?
173. Simvastatin-oral anticoagulant interaction
174. Bilateral subdural haematoma caused by simvastatin during warfarin treatment
175. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin
176. Atorvastatin does not alter the anticoagulant activity of warfarin
177. Potential interaction between warfarin and fluvastatin
178. Potential warfarin-fluvastatin interaction
179. No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin
180. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolaemic volunteers
181. Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin
182. Atorvastatin: A hydroxymethylglutaryl-coenzyme A reductase inhibitor
183. Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine
184. Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine
185. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: Erythromycin and ethinyl estradiol
186. Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: Prospective nested case-control study
187. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?
188. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin study (REGRESS)
189. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypercholesterolaemic therapy on coronary atherosclerosis in angiographic trials
190. Early statin treatment following acute myocardial infarction and 1-year survival
191. Statins do more than just lower cholesterol
192. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolaemia
193. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
194. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolaemia and systemic hypertension
195. Beyond lipids - The role of the endothelium on coronary artery disease
196. Hydroxymethylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance
197. Antithrombotic properties of statins
198. Effects of long-term treatment with lovastatin on the clotting system and blood platelets
199. Hypercholesterolaemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
200. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolaemia. Effects of pravastatin
201. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy
202. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long term simvastatin treatment
203. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells
204. Pro-apoptopic effect of fluvastatin on human muscle cells
205. Do statins prevent both cardiovascular disease and fracture?
206. Partial remission of nephrotic syndrome in patients on long-term simvastatin
207. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
208. HMG-CoA reductase inhibitors and the risk of fractures
209. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension
210. The renaissance of C reactive protein: It may be a marker not only of acute illness but also of future cardiovascular disease
211. Long-term effects of pravastatin on plasma concentration of C-reactive protein
212. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease
213. Effect of pravastatin on outcomes after cardiac transplantation
214. Mechanisms modifying atherosclerotic disease-from lipids to vascular biology
215. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
216. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
217. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
218. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil
219. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolaemia
220. Clinical pharmacokinetics of fibric acid derivatives (fibrates)
221. Interactions with hydroxymethyl-CoA reductase inhibitors
222. Safety of combined pravastatin-gemfibrozil therapy
223. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers
224. The hypolipidaemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia
225. Rhabdomyolysis after taking atorvastatin with gemfibrozil
226. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
227. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil
228. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy - A case report
229. Treatment of heterozygous familial hypercholesterolaemia with lipid-lowering drugs
230. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia
231. Antihyperlipidaemic agents: Drug interactions of clinical significance
232. Lovastatin, nicotinic acid, and rhabdomyolysis
233. Fluvastatin with and without niacin for hypercholesterolaemia
234. Efficacy and safety of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidaemia: A prospective trial
235. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia
236. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin
237. Hyperlipidaemia in solid organ transplantation
238. Approaches to the treatment of hyperlipidaemia in the solid organ transplant recipient
239. Drug treatment of lipid disorders
240. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients
241. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolaemia in renal transplant patients receiving cyclosporine
242. The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients
243. Effects of simvastatin and pravastatin on hyperlipidaemia and cyclosporin blood levels in renal transplant recipients
244. Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation
245. Rhabdomyolysis in heart transplant patients on HMG-Co-A reductase inhibitors and cyclosporine
246. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation
247. The interaction of fluvastatin and cyclosporin A in renal transplant patients
248. Fluvastatin in renal transplantation
249. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinaemia